Hiv vaccine research trials

Common Questions and Answers about Hiv vaccine research trials

hiv

101028 tn?1419603004 http://www.siumed.edu/pubs/aspects/Summer2010/feature4_33-3.html this isn't in human studies yet but felt it was an update worth sharing. will post when trials start too.
Avatar f tn Grace, I was reading through some older posts and I have seen that you stated Dr. Halford was doing some interesting research on a vaccine but it was a risky but it was using a live virus. I was wondering if you have any updates on his research? It was mentioned in a post late in 2011. I have tried to find some information online without sucess. Any ideas on the outcome of this? Thanks in advance.
Avatar f tn Lyme compared to HIV/AIDS By a well known Lyme specialist---- Dr. J. in Washington D.C.---- in his remarks read to the North Carolina Medical Board during his final appearance before them on July 20, 2006. "Most of my HIV patients used to die ... now most don't ... Some still do, of course. My Lyme patients, the sickest ones, want to die but they can't. That's right, they want to die but they can't. The most common cause of death in Lyme disease is suicide.
373367 tn?1246402035 t I read where they have only tried it one 30 patients? I think they should step up their research to include more individuals and get on done, SOON. Thanks for posting this. They are truly making advances in the fight against diseases.
559053 tn?1274913374 s an accomplishment that many thought was impossible. Because hepatitis C is more virulent than HIV, no one was confident a vaccine against all the various strains around the world could be developed. But Michael Houghton, the University of Alberta researcher who announced his work today at the Canada Excellence Research Chairs Summit in Vancouver, says his vaccine works against every known strain of the virus.
Avatar f tn 6 million ($49 million) in a European IPO, earmarking its new cash to push a hepatitis B vaccine into pivotal trials and hit the gas on an HIV drug. Abivax has registered about 2 million shares on the Euronext Paris exchange, setting aside another roughly 300,000 for its underwriters. The biotech will be placing shares through June 22, expecting to price them at a midpoint of €21.30 ($23.91) each. If Abivax's overallotment allocation comes through, the company could gross €57.
Avatar m tn Do you know if that research is going to continue? I believe I read that Pritelivir was in Phase II trials, so if the research started again what would be a realistic time frame for when the drug could be publicly available? Are there any other more promising drugs in the pipeline that might be available sooner? Another source I have been reading about is Dr William Halford (http://www.huffingtonpost.com/2015/03/03/herpes-vaccine_n_6791538.
55646 tn?1263660809 After years of nothing new in herpes research, everything is new right now. Nationally, there are at least three different studies beginning for the treatment of genital herpes. First, the Genocea phase one (first in humans) trial. Instead of an oral medication to treat herpes, Genocea out of Boston has taken the approach of stimulating the immune system to respond more robustly to the herpes virus in people who are already infected with the virus.
Avatar m tn also of note is Admedus received approval to go to Phase 2 clinical trials for their HSV2 vaccine around Xmas last year. They expect interim results sometime this year. Dr. Cullen at Duke is commencing mouse trials for a cure: http://cullenlab.duhs.duke.
Avatar m tn Recent trials on animals have shown it is between 85 and 100 per cent effective at blocking HIV and Herpes transmission. 4. Astellas ASP-2151 The most promising of the long-awaited Helicase Primase Inhibitors (HPI) drugs. And I really mean long-awaited. This is like super-acyclovir, and there's been some speculation that it could inhibit the virus so effectively that asymptomatic shedding may not be an issue. 5.
Avatar n tn As I understand it, there is therapeutic vaccine in the effectiveness trials at the University of Queensland, Australia. (Sorry I am not up on the lingo here the "safety trials" have been successfull) It is based on the Gardasil Vaccine. What is the likely effectiveness of the therapeutic vaccine? (It isn't a flat out cure is it?) Can you direct me to any other promising research being done?
Avatar m tn I'm referring to this latest news about hiv research which is also a retrovirus like hbv: http://www.telegraph.co.uk/news/2016/10/02/hiv-cure-close-after-disease-vanishes-from-blood-of-british-man/ "The new therapy works in two stages. Firstly, a vaccine helps the body recognise the HIV-infected cells so it can clear them out. Secondly, a new drug called Vorinostat activates the dormant T-cells so they can be spotted by the immune system.
167426 tn?1254086235 A vaccine for ovarian cancer has produced "encouraging" results in preliminary trials, US scientists say. The vaccine is designed to enhance the body's own immune response to the cancer, said the Roswell Park Cancer Institute, based in Buffalo, New York. Most patients with advanced disease respond to chemotherapy, but more than 70% die from a recurrence of the cancer within five years of diagnosis. Cancer Research UK welcomed the study but said further trials were needed.
Avatar n tn I've heard that the new hiv vaccine is being tried on humans, and it worked on preventing hiv infection in monkeys. does this look promising, anyone thing that this vaccine will eventually work within 5 yrs or less, anyone got more infos on this. How about u teak, have u heard anything, are those people on the trial being protected?
167426 tn?1254086235 The Cancer Vaccine Collaborative program is a partnership between CRI and the Ludwig Institute for Cancer Research, which coordinates cancer vaccine trials using defined novel antigens, standardized treatment protocols, uniform monitoring methodologies, and data collection. The Cancer Research Institute was founded in 1953 to foster the science of cancer immunology, which is based on the premise that the body’s immune system can be mobilized against cancer.
163305 tn?1333668571 Because hepatitis C is more virulent than HIV, no one was confident a vaccine against all the various strains around the world could be developed. But Michael Houghton, the University of Alberta researcher who announced his work today at the Canada Excellence Research Chairs Summit in Vancouver, says his vaccine works against every known strain of the virus.
Avatar m tn Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.
Avatar n tn Vaccine Campaigns May Be The Cause of New AIDS-Like Disease in Asia and Drug Resistant HIV Affecting Africa Researchers have identified mysterious new symptoms that have left scores of people in Asia and sub-Saharan Africa with an AIDS-like disease and drug-resistant HIV respectively. Coincidentally, vaccine trials took place in several regions in both continents. The patients' immune systems become damaged, leaving them unable to fend off germs as healthy people do.
Avatar m tn Last thing I read about it was that scientists were trying to invent a genome that would lure the virus out of its hiding place in the nerve cells. Then they would give you the anti-viral drug like acyvalvolir (don't know how to spell it) and that would kill it. The risk is that you would face an outbreak of the virus though. That's the only thing I heard about a cure, they're also trying to make a vaccine for it for kids but nothing successful has been made yet.
Avatar m tn Partners and collaborators include the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com. For further information: Roche Partnering Emilie Vincent, Head of Roche Partnering Communications, emilie.